These purely synthetic galectin-3 compound inhibitors are shown to effectively inhibit galectin-3 binding to its ligands, galectin-3-mediated cancer cell activities in vitro and significantly reduce tumour growth and metastasis in vivo in chick embryos and in mice. The gene discussed is LGALS3; the disease is neoplasm.